TLDR: GlobalData has announced a significant advancement in pharmaceutical research with its enhanced AI-powered Likelihood of Approval (LoA) model, which can predict drug approvals with an 85% success rate, streamlining the drug development process.
LONDON – September 26, 2025 – GlobalData, a leading data and analytics company, has unveiled a groundbreaking enhancement to its Artificial Intelligence (AI) powered Likelihood of Approval (LoA) model. This sophisticated tool is now capable of predicting pharmaceutical drug approvals with an impressive 85% success rate, marking a pivotal moment for the pharmaceutical industry.
The enhanced LoA model leverages advanced AI algorithms to boost its predictive power, offering a high probability of a drug receiving market authorization. This development is expected to significantly impact drug development timelines and resource allocation, allowing pharmaceutical companies to make more informed decisions earlier in the pipeline.
The pharmaceutical sector has been increasingly looking towards AI to revolutionize its research and development (R&D) processes. Earlier this year, GlobalData highlighted in its ‘The State of the Biopharmaceutical Industry – 2025’ report that AI is poised to enhance R&D productivity and reduce costs. Urte Jakimaviciute, Senior Director of Market Research and Strategic Intelligence in GlobalData’s healthcare division, emphasized the critical role of improving R&D productivity to accelerate new drug development, respond to emerging medical needs, and maintain a competitive edge. The integration of AI, she noted, aligns with a broader industry trend towards digitalization and efficiency.
Industry professionals have identified AI’s most effective integration points in drug discovery as lead generation and optimization, followed by target identification. While AI’s role in drug discovery is still evolving, with many AI-discovered drugs in early clinical stages, the continuous advancements in AI, coupled with the need for speed, cost-effectiveness, and increasing regulatory acceptance, are expected to drive a surge in AI-discovered drugs entering the market.
Also Read:
- Salesforce Unveils Advanced AI Agents to Revolutionize Customer Engagement in Life Sciences
- Healthcare’s Generative AI Revolution: Opportunities and Obstacles
This latest achievement by GlobalData underscores the transformative potential of AI in healthcare, offering a data-driven approach to navigate the complex and costly path of drug development and approval. The 85% success rate of the LoA model provides a robust tool for stakeholders to assess potential drug candidates, ultimately aiming to bring life-saving medications to patients more efficiently.
